Rhinovirus infection MedDRA version: 18.1 Level: LLT Classification code 10039107 Term: Rhinovirus infection NOS System Organ Class: 100000004862
Conditions
Interventions
Trade Name: Pegasys
Pharmaceutical Form: Injection
INN or Proposed INN: PEGINTERFERON ALFA-2A
CAS Number: 198153-51-4
Concentration unit: µg microgram(s)
Concentration type: equal
Concentration number
Sponsors
Turku University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Adult patients (>18 years), primary hypogammaglobulinemia with regular immunoglobulin replacement therapy, rhinovirus positive from nasal swab, thrombocytes over 90 x10E9/L Neutrophiles > 1,5 x10E9/L and written informed consent. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 15 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 5
Exclusion criteria
Exclusion criteria: Participation to another study, need for intensive care unit treatment, difficulties to understand national language, pregnancy and breastfeeding, any somatic, psychiatric or social disease or issue which in the opinion of the investigator makes participation in the trial not being in the best interest of the subject.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: The study will investigate the efficacy and safety of subcutaneous interferon alpha -2a to eradicate rhinovirus in patients with primary hypogammaglobulinemia. ;Secondary Objective: Not applicable.;Primary end point(s): Not applicable.;Timepoint(s) of evaluation of this end point: Not applicable. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): Not applicable.;Timepoint(s) of evaluation of this end point: Not applicable. | — |
Countries
Finland
Contacts
Public ContactTurku University Hospital
Turku University Hospital
Outcome results
None listed